Objective: To explore the relative association of admission blood glucose levels and antecedent diabetes on early and long-term survival in a contemporary UK population of patients with ST elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI).
▪ In patients with both STEMI as well as NSTEMI, admission glucose is more strongly associated with mortality than is antecedent diabetes diagnosis. ▪ The increased risk associated with admission glucose is evident during the index admission, at 30 days, 1 year and beyond and is apparent in those surviving to discharge. ▪ Conversely, after multivariate adjustment for covariates, including admission glucose is not associated with mortality.
Strengths and limitations of this study
▪ This is a study of a large cohort of patients with both STEMI and NSTEMI managed in contemporary clinical practice in a tertiary care centre. ▪ A statistically robust association was seen for admission glucose with both short-term and long-term mortality after adjusting for many important confounders. ▪ Our data lack information on glucose-lowering intervention, patients with undiagnosed diabetes and other potentially relevant variables which were not considered in the analysis.
INTRODUCTION
For patients with acute myocardial infarction (AMI) the risk of adverse outcome is increased by the concomitant diagnosis of diabetes mellitus (diabetes). 1 2 In addition, elevated blood glucose concentration, a common finding at admission in patients with AMI, is also associated with increased risk of adverse outcome, irrespective of prior diabetes. [1] [2] [3] [4] [5] [6] [7] [8] In some studies 4 9 the association between admission blood glucose concentration and adverse outcome was more powerful in patients without, compared to those with, prior diabetes. Indeed, we previously reported more powerful association with 30-day and 1-year mortality after ST elevation myocardial infarction (STEMI) for admission blood glucose concentration, compared to the diagnosis of diabetes. 9 While a causal relationship is unproven, there are numerous potential pathophysiological mechanisms by which hyperglycaemia may impart toxicity during myocardial ischaemia. 10 11 Indeed, observational data suggest that elevated blood glucose may contribute directly to adverse outcome after AMI. Prognosis is worse for patients in whom hyperglycaemia persists in the 24-48 h after AMI compared to those in whom blood glucose normalises. 12 13 In patients without prior diabetes, insulin-based treatment of hyperglycaemia after AMI is associated with improved prognosis. 14 15 Further, in randomised, controlled trials (RCTs) of intensive, insulin-based blood glucose management during admission with AMI, survival benefit was evident only when intervention effectively lowered blood glucose concentration. 16 17 While the relationship between blood glucose concentration and outcome after AMI has largely been described in patients with STEMI, the majority of acute coronary syndromes in contemporary practice are non-ST elevation AMI (NSTEMI). The aim of the current analysis was to compare the relative strength of association with 30-day and 1-year mortality of antecedent diabetes diagnosis and admission blood glucose concentration in patients with STEMI and with NSTEMI, and in those with and without a history of diabetes, in a multiethnic population. We also assessed the relevance of blood glucose concentration, recorded soon after admission to hospital with AMI, to mortality in patients surviving to discharge. 18 we record clinical and demographic data including information on diagnosis (STEMI/NSTEMI), ECG site of infarct, medical history, coronary heart disease risk factors and prescribed medication. Data are record-linked to mortality information 19 and include self-reported coding for ethnicity, for which local coverage is thorough. Approximately 10% of the local population are of South Asian ethnic origin, over twice the UK national average.
METHODS
Patients were categorised as having a diagnosis of diabetes if this was self-reported by the patient, or on the basis of medication prescribed prior to admission. All patients with AMI routinely underwent blood glucose measurement, in most cases within first 12 h after admission with their blood samples assayed in the hospital laboratory. We used such first-recorded admission glucose levels for this analysis. All diagnoses of AMI were verified prior to submission to the national MINAP database; the diagnosis of AMI was made according to the joint ESC/ACCF/AHA/WHF definition. 20 Patients were categorised as STEMI or NSTEMI, according to the final discharge diagnosis recorded in the MINAP database. For patients with multiple AMI admissions during the study period, we considered only the first event. The number of cases admitted with AMI during the study period determined the sample size.
Survival was measured from the date of first admission to the date of death or of censoring at 30 September 2009. Mortality data are supplied to the hospital on a monthly basis via the UK Office for National Statistics. Follow-up data on mortality were available for all the patients. The predefined primary outcome measure was 30-day, and 1-year, all-cause mortality.
The study was approved by the local research ethics committee. The data used in this analysis were gathered during routine care and as part of the MINAP 18 mandatory requirement for all acute hospitals in England and Wales to collect data pertaining to admission with AMI.
Statistical analysis
Baseline characteristics were compared between groups using independent two-sample t tests for continuous variables and χ 2 tests for categorical variables. Mortality at 30 days and at 1 year, in the entire cohort, and in those patients surviving to discharge, was calculated.
We calculated mortality proportions for patients admitted from 1 October 2002 to 30 September 2008 with follow-up censored at 30 September 2009. Survival probabilities were calculated using Kaplan-Meier (KM) analyses and patient groups compared using survival analysis log rank test. Relative risk of mortality, as a function of clinical variables, was examined using Cox proportional hazards techniques. We initially assessed the unadjusted, univariate association with outcome for admission blood glucose and for diabetes, and for other potentially relevant clinical and demographic variables (age, sex, ethnicity (White European, South Asian), smoking, type of AMI (STEMI, NSTEMI), prior history (hypertension, any coronary artery disease, cerebrovascular or peripheral vascular disease), admission systolic blood pressure and heart rate, estimated glomerular filtration rate (eGFR), coronary revascularisation during index admission, preadmission and discharge drug therapy (antiplatelet, β-blocker, statin, ACE inhibitor/angiotensin receptor blocker) and index loop diuretic use). An interaction term representing calendar year of admission was included to adjust for potential temporal changes in the management of acute coronary artery disease.
Demographic and clinical covariates with univariate association ( p<0.10) with mortality at 30 days or 1 year were entered into multivariate models (Cox proportional hazards). All quantitative variables were entered as continues variables into the model. Patients with missing data (table 1) were not excluded but their values were set as missing. Statistical significance for all comparisons was set at p<0.05 (two-sided). Data are presented as HR and 95% CI. We used fractional polynominals to model admission glucose to account for any non-linearity and assessed its independent association with mortality in subgroups with and without diabetes. Analyses were carried out using SPSS V.18. During the index admission administration of loop diuretic was more frequent (52.7% vs 33.4%, p<0.005) and, for patients with STEMI, coronary reperfusion therapy less frequent (50.2% vs 60.9%,<0.005), in patients with diabetes. Other than for slightly less use of β-blockers and aspirin in patients with diabetes, patterns of prescription of secondary prevention therapies at discharge were similar in the two groups.
Mortality-univariate analysis Deaths during hospitalisation, over 30 days, 1 year and the entire period of follow-up numbered 319 (7.8%), 409 (9.9%), 677 (16.5%) and 1041 (25.3%), respectively. Age, female sex, higher admission heart rate, higher eGFR, lower systolic blood pressure and presentation with STEMI (compared to NSTEMI), as well as prior smoking and hypertension, each showed univariate association with mortality risk over all time periods (table 2) . Loop diuretic was associated with a 3-4 fold increase in mortality during follow-up. Survival improved over the period of observation.
Prior diabetes showed strong univariate association with mortality risk over all time periods: HR 30 days 1.40 (1.12 to 1.75); 1 year 1.58 (1.33 to 1.86); all follow-up 1.66 (1.44 to 1.90; table 2). The strength of association between glucose and mortality was consistent at 30 day and at 1 year, each mmol/l increase in admission glucose concentration being associated with a 6-7% increase in hazard of mortality over all time periods.
Postdischarge mortality
In those surviving to discharge (N=3792), 106 (2.8%), 363 (9.6%) and 726 (19.1%) died by 30-day, 1-year and over all follow-up (see online supplementary table S2A). Univariate associations with mortality were similar to those in the entire population. Prior diabetes showed univariate association with increased risk of death at all times, although this was not statistically significant at 30 days (HR 1.36, (0.87 to 2.12)). For admission glucose, the strength of association with postdischarge mortality was very similar to that in the entire cohort, with 5-7% increase risk per mmol/l increase in glucose (see online supplementary table S2A). Table 3 shows the results of multivariate analysis. Age, lower admission systolic blood pressure and higher heart rate, lower eGFR, prescription of loop diuretic and STEMI (compared to NSTEMI) each retained independent association with mortality, as did prescription of individual discharge medications. After covariate adjustment, diabetes did not retain independent association with mortality at any time. In contrast, adjustment for covariates had little impact on the risk of mortality associated with admission glucose concentration.
Mortality-multivariate analysis

Postdischarge mortality
For patients surviving to discharge, associations between clinical variables and the risk of mortality were similar to those seen in the entire cohort (see online supplementary table S3A). While there was no association between prior diabetes and risk of mortality at any time (HR 30 days 0.64 (0.31 to 1.300); 1 year 0.91 (0.66 to 1.26); all follow-up 1.08 (0.86 to 1.36)), blood glucose retained powerful association with the primary endpoint. This was evident at 30 days (HR per mmol/l 1.10, 95% CI 1.05 to 1.15), 1 year (1.05, 1.02 to 1.08) and over all follow-up (1.04, 1.02 to 1.06)).
Admission glucose concentration: influence on mortality in patients with or without diabetes We repeated multivariate analysis including a term for interaction between diabetes diagnosis and admission glucose concentration. While numerically greater in individuals without diabetes (figure 1), there was no conventional statistically significant difference in the association between mortality and admission blood glucose for patients with and without diabetes (30 days HR 1.00 (95% CI 0.97 to 1.03, p=0.95; 1 year 0.99, (0.97 to 1.02), p=0.66; entire follow-up 0.99, (0.97 to 1.01, p=0.42)).
Diabetes and glucose after AMI: influence on mortality in STEMI and NSTEMI After adjustment for covariates, diabetes showed no statistically significant association with mortality at any time period, either for STEMI or NSTEMI (table 4). The strength of association between blood glucose and mortality was very similar in the first 30 days after STEMI or NSTEMI. The strength of this relationship declined with time only after NSTEMI.
DISCUSSION
It is well known that both prior diabetes diagnosis and admission blood glucose concentration are associated with adverse outcome after AMI. In this report, we compared the relative association of these two measures of dysglycaemia with survival after STEMI as well as NSTEMI. Irrespective of the type of AMI, the univariate association with mortality risk for antecedent diabetes (40% excess at 30 days, 55-65% thereafter) was no longer apparent after adjustment for relevant covariates including admission glucose concentration. In contrast, the excess risk associated with increasing glucose was not reduced after adjustment, was similar in those with and without known diabetes, and remained relevant in patients discharged alive from the index event.
In our previous report of over 4000 patients with STEMI, admitted in 1993-2004, 9 the 50% increase in 30-day and 1-year mortality risk associated with known diabetes was attenuated by half on covariate adjustment and removed completely when admission blood glucose concentration was included in the analysis. The current report confirms these observations and extends them to a contemporary period, and to patients with NSTEMI as well as STEMI, in whom the strength of association between admission blood glucose concentration and 30-day mortality risk was similar, and concentration dependent. Importantly, the excess risk, around 7% for each 1 mmol/l increase in admission glucose concentration, was maintained up to and beyond 1 year from the index infarction. Further, this phenomenon was attenuated with time only for patients with NSTEMI, and was evident even in those patients who survived to discharge from hospital, two potentially important clinical observations. These findings are in contrast to one previous report which reported the association between admission glucose and mortality to be confined to in-hospital deaths following either STEMI or NSTEMI. 8 They are however in keeping with the vast majority of reports in this area.
1-7 9 11
In contrast to most previous reports, 1-9 11 we observed no independent association between diabetes and mortality risk after AMI. However, to our knowledge and unlike the present report, none of these studies adjusted for admission blood glucose, and each reported individual relationships between mortality after AMI and either diabetes diagnosis 1 2 4 8 or blood glucose concentration.
3-8 11-13 21 The current analysis and our previous study 9 are the only reports to compare the relative association with outcome of both diabetes and blood glucose concentration. Both studies demonstrate a much stronger relationship between survival and blood glucose, and the loss of association between mortality and diabetes when blood glucose is considered. Owing to incomplete data and lack of power, we could not assess whether outcomes varied by diabetes therapies. However, previous studies have reported an independent association of admission blood glucose with mortality regardless of diabetic therapy used. 2 5 7 These observations are of potential clinical significance. While admission blood glucose concentration after AMI is on average higher in patients with, compared to those without, known diabetes, 4 8 9 there is considerable overlap, as seen in the current report ( figure  1 ). While many patients presenting with AMI will have previously undiagnosed diabetes, 22 blood glucose at the time of admission with AMI is not a reliable indicator of the subsequent diagnosis of diabetes. 23 24 In routine practice, the management of hyperglycaemia after AMI is influenced by the presence of prior diabetes diagnosis. 5 In both European 14 and North American 6 settings, the majority (>65%) of patients presenting with hyperglycaemia in the context of AMI, and not previously known to have diabetes, do not receive active management of blood glucose. In the presence of a true, direct toxic effect upon prognosis of elevated blood glucose, failure to correct hyperglycaemia may represent suboptimal clinical care, and patients without known diabetes may be particularly disadvantaged. In particular, our demonstration that the relationship between glucose concentration and subsequent outcome is evident in NSTEMI as well as STEMI is of clear clinical relevance in terms of the overall management of patients presenting with AMI.
The strength of association between diabetes and mortality risk after AMI has been reported to increase with time from the event. 25 While we observed such a trend on univariate analysis, this was attenuated in multivariate analysis, an observation which may relate to our inclusion of blood glucose as a covariate. A previous meta-analysis suggested a stronger association between admission blood glucose and adverse outcome. 4 While we could not demonstrate formal statistical evidence of such a phenomenon, our data show convincingly that the relationship between glucose and outcome is at least as powerful in patients without known diabetes. Blood glucose soon after admission represents an easily identified, clinically relevant marker of risk after AMI, which should be assessed routinely irrespective of diabetes status. An important observation from this study is the persisting association between admission blood glucose concentration and mortality risk in patients surviving to discharge, in both NSTEMI and STEMI. While in keeping with the possibility that blood glucose concentration at admission reflects the degree of individual physiological stress, or is a marker of the extent of infarction, our findings are as much in keeping with a direct, adverse influence on prognosis of acute hyperglycaemia. The mechanisms by which elevated glucose may be directly cardiotoxic have been summarised elsewhere 10 and include attenuation of ischaemic preconditioning, QT prolongation, increased thrombophilia and endothelial dysfunction. Furthermore, clinical studies overwhelmingly support a possible causal link between hyperglycaemia and adverse prognosis after AMI. Hyperglycaemia persisting at 24 h after admission is associated with adverse outcome. 12 13 17 While observational studies show consistently the adverse association between hyperglycaemia and outcomes post-AMI, results of the RCTs of active management of blood glucose have been inconsistent. 16 17 However, in such trials, effective reduction in blood glucose with an intervention after AMI was associated with improved prognosis. 16 The guidelines from professional societies in this area differ in their recommendations. 26 27 In the North American guidelines, intensive glucose control is recommended in patients with AMI and significant hyperglycaemia (blood glucose levels >10.0 mmol/l) admitted in an intensive care unit. 27 In contrast, the National Institute for Health and Clinical Excellence guidance recommends against routine use of intensive insulin therapy to manage hyperglycaemia (blood glucose levels >11.0 mmol/l) in patients with acute coronary syndrome. 26 The latter guidelines highlighted a need for randomised controlled trials addressing specific gaps in knowledge this area.
Our report is subject to the limitations inherent in all observational cohort studies. Our results are from a singlecentre study. In the early years of the MINAP project, data on only STEMI were collected. Furthermore, data collected for MINAP was gathered mainly from a setting of coronary care unit. Selection bias could be the reason behind the overall low numbers of AMI cases (4111) recruited in our study over a 6-year period in a catchment population of one million. However, baseline and clinical outcome parameters in our study are similar to previous studies. Selection bias could also explain relatively high proportion of patients with STEMI (58.4%) compared to NSTEMI in our cohort. We therefore conducted subgroup analysis for people with STEMI and NSTEMI and compared their outcomes. Blood glucose concentration used in this analysis was that first recorded for the index admission, and is likely to have varied in timing relative to symptom onset. Our database lacks information on left ventricular (LV) ejection fraction, evidence of heart failure and a number of other potentially relevant variables. Information on body mass index, an indicator of underlying metabolic syndrome and associated dysglycaemia, was not available. Further, we have no information regarding the number of patients who were given a diagnosis of diabetes during, or subsequent to, the index admission. However, if elevated glucose contributes directly to prognosis, active management is likely to confer greater benefit when delivered as early as possible, irrespective of subsequent diabetes status. Thus, we suggest the first-recorded blood glucose concentration to be highly relevant to guiding appropriate management in individual patients, irrespective of residual LV function. While we have no information on interventions or changes to therapy after discharge, it is unlikely that these impacted on outcome in a major way, as the strongest association between mortality and glucose was in the first 30 days. Findings of our study based on real-life practice are applicable to other populations treated in similar setting.
In summary, admission blood glucose concentration is a powerful, routinely available marker of mortality risk after AMI. After adjustment for admission blood glucose, known diabetes is not associated with adverse outcome. The association between blood glucose concentration and mortality risk is of similar magnitude in patients with and without known diabetes, is evident for NSTEMI as well as STEMI, and persists beyond 1 year from the index event, including in patients surviving to discharge. Future studies are merited of the impact of active management of blood glucose in patients with all presentations of acute coronary artery disease, irrespective of diabetes diagnosis.
